Clofutriben is under clinical development by Sparrow Pharmaceuticals and currently in Phase II for Cushing’s Syndrome. According to GlobalData, Phase II drugs for Cushing’s Syndrome have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Clofutriben’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Clofutriben overview

Clofutriben is under development for the treatment of Cushing's syndrome, polymyalgia rheumatica, autonomous cortisol secretion. It is administered through the oral route in the form of tablet and also administered through intraocular, topical routes. It is a new chemical entity and acts by targeting 11 beta-hydroxysteroid dehydrogenase type 1 (HSD1).

Sparrow Pharmaceuticals overview

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company that develops novel therapies for endocrinology and rheumatology diseases. The company’s pipeline products include SPI-62 and SPI-47. Its SPI-62 is an oral, small molecule, highly potent and selective new chemical entity HSD-1 inhibitor that treats conditions of excess cortisol including endogenous Cushing’s syndrome and autonomous cortisol secretion (ACS). The company’s SPI-47 is an HSD-1 inhibitor that treats polymyalgia rheumatica (PMR). Sparrow Pharmaceuticals is headquartered in Portland, Oregon, the US.

For a complete picture of Clofutriben’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.